Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...